Lipocine Inc. $LPCN

What the company doesAI summary of filing

Lipocine Inc. is a biopharmaceutical company developing oral drug delivery solutions for difficult-to-deliver molecules. The company has licensed its FDA-approved product TLANDO (testosterone undecanoate for testosterone replacement therapy) to multiple partners including Verity Pharmaceuticals for the U.S. and Canada, SPC Korea for South Korea, Pharmalink for Gulf Cooperation Council countries, and Aché for Brazil, and receives milestone payments, royalties, and supply revenues from these agreements. The company is clinical-stage for its pipeline of candidates targeting central nervous system disorders (LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor), liver disease (LPCN 1148), obesity management (LPCN 2401), and preterm birth prevention (LPCN 1107), and is exploring partnerships for further development of these candidates. [10-K 2026-03-10]

Segments: TLANDO (testosterone replacement therapy), LPCN 1154 (postpartum depression), LPCN 2201 (major depressive disorder), LPCN 2101 (epilepsy)